A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.

Authors

• William Kelly

Publication/Presentation Date

3-2017

Volume

35

Issue

6

Published In/Presented At

DOI: 10.1200/JCO.2017.35.6_suppl.80

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article